Company intelligence / Profile preview

Kinentia Biosciences

Rensselaer / Albany area, New York, United Stateskinentia.com ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

Kinentia Biosciences provides contract research and manufacturing services across the drug discovery and development spectrum using its proprietary Deep Data Mining platform. It supports clients from early discovery through commercialization with GLP and c-GMP facilities in the US. The company is currently involved in exclusive US manufacturing of TC220, a novel boronated amino acid analog for BNCT cancer therapy that has shown improved tumor targeting over conventional agents in preclinical studies.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologic (manufacturing capabilities include biologics)
Industry: Contract Research Organization

Partnerships

TAE Life Sciences (exclusive US manufacturer of TC220)Biddle Sawyer Corp. (distribution/supply partnership for TC220)

Beyond the preview

Go deeper on Kinentia Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinentia Biosciences.